FindTrial
Sign In

Effect of resveratrol combined on Exercise program on health-related outcomes of breast cancer survivors: randomized, double-blind clinical trial

Effect of resveratrol combined on Exercise program on health-related outcomes of breast cancer survivors: randomized, double-blind clinical trial - Womber Women moving beyond Breast Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-87g6ny8
Enrollment
Unknown
Registered
2021-12-08
Start date
2018-02-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

SP6.051.227
Home-based exercise group with Resveratrol: The 20 participants in this group will do 12 weeks of aerobic exercise associated with strength exercise with their own body weight and flexibility of moder
G11.427.410.698.277

Sponsors

Universidade Federal de Pernambuco
Lead Sponsor
Fundação de apoio à Ciência e Tecnologia de Pernambuco - FACEPE
Collaborator

Eligibility

Sex/Gender
Female
Age
45 Years to 75 Years

Inclusion criteria

Inclusion criteria: Postmenopause; high BMI; sedentary lifestyle (mild physical activity, less than 150 minutes per week, American College of Sports Medicine 2014)

Exclusion criteria

Exclusion criteria: Recurrence of breast cancer; bone metastasis; bone fractures; severe anemia; platelet count less than 50x109ml; participation in other physical exercise programs.

Design outcomes

Primary

MeasureTime frame
Improvement of body composition, decrease in BMI and fat percentage, and maintenance of bone density, evaluated by a scale and a stadiometer, Filizola, São Paulo, Brazil, with an accuracy of 0.1 kg and 0.5 cm, respectively. As well as the percentage of fat and bone density, assessed by the x-ray double-beam absorptiometry method, with model equipment, Lunar Prodigy Primo, GE Healthcare. Data collected 1 week before the intervention and one week after the intervention ended.;Inflammatory profile modulation, assessed by a blood collection of 4 ml of blood per tube to obtain plasma for cytokine analysis: IL-6, IL-1, IL-4, IL-10, TNF, and IFN. The samples will be analyzed by flow cytometry, Accuri C6 CSampler, BD Biosciences, and the data obtained were analyzed with FCAParray software, BD Biosciences. Blood tests collected 1 week before the intervention and one week after the intervention ended.;Improvement of cardiorespiratory capacity, assessed by submaximal aerobic test by Swain et al. SUPRA ATL treadmill, IMBRAMED, Brazil) and using the RS800CX, Polar Electro Oy Finland, frequency meter. The maximum VO2 will be estimated by the reserve HR and VO2 equations, the protocol of the American College of Sports Medicine. Data collected 1 week before the intervention and one week after the intervention ended.—

Secondary

MeasureTime frame
No Secondary Outcomes Expected;No Secondary Outcomes Expected—

Countries

Brazil

Contacts

Public ContactFabricio Souto

Universidade Federal de Pernambuco

soutofo@gmail.com+55-81-981251146

Outcome results

None listed

Source: REBEC (via WHO ICTRP)